- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
Authors
Keywords
-
Journal
Journal of Immunology Research
Volume 2021, Issue -, Pages 1-11
Publisher
Hindawi Limited
Online
2021-11-09
DOI
10.1155/2021/7855808
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Restoring IL-2 to its cancer immunotherapy glory
- (2021) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
- (2021) Eric J. Hsu et al. Nature Communications
- Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
- (2021) Adi Diab et al. JOURNAL OF CLINICAL ONCOLOGY
- An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism
- (2021) Jerod L. Ptacin et al. Nature Communications
- CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
- (2020) Steven N Quayle et al. CLINICAL CANCER RESEARCH
- Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
- (2020) Giulia Parisi et al. Nature Communications
- Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
- (2020) Meenu Sharma et al. Nature Communications
- Immunocytokines are a promising immunotherapeutic approach against glioblastoma
- (2020) Tobias Weiss et al. Science Translational Medicine
- Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells
- (2019) Cornelia Hutmacher et al. Cancer Immunology Research
- Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
- (2019) Dario Neri Cancer Immunology Research
- Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti–PD-1 in melanoma
- (2019) Laurene S. Cheung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- Effects of interleukin-2 in immunostimulation and immunosuppression
- (2019) Jonathan G. Pol et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
- (2019) Zhichen Sun et al. Nature Communications
- Signaling and Function of Interleukin-2 in T Lymphocytes
- (2018) Sarah H. Ross et al. Annual Review of Immunology
- Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
- (2018) Michael Dougan et al. Cancer Immunology Research
- Cytokines in clinical cancer immunotherapy
- (2018) Pedro Berraondo et al. BRITISH JOURNAL OF CANCER
- Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
- (2018) Lorenzo Mortara et al. Frontiers in Immunology
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- (2017) Frederick Arce Vargas et al. IMMUNITY
- Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin
- (2017) Esben G. W. Schmidt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cytokines in Cancer Immunotherapy
- (2017) Thomas A. Waldmann Cold Spring Harbor Perspectives in Biology
- Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
- (2017) Rodrigo Vazquez-Lombardi et al. Nature Communications
- Regulatory T cells control toxicity in a humanized model of IL-2 therapy
- (2017) Yan Li et al. Nature Communications
- Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
- (2017) Deborah Charych et al. PLoS One
- Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancer
- (2016) Xi Chen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
- (2016) Reza Ghasemi et al. Nature Communications
- Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
- (2015) Eric F. Zhu et al. CANCER CELL
- FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
- (2015) Michal Pyzik et al. JOURNAL OF IMMUNOLOGY
- NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
- (2015) Michel M van den Heuvel et al. Journal of Translational Medicine
- Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma
- (2015) Sébastien Wieckowski et al. LUNG CANCER
- The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer
- (2015) Chiara Catania et al. Cell Adhesion & Migration
- Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
- (2015) Kine Marita Knudsen Sand et al. Frontiers in Immunology
- Advances in NKG2D ligand recognition and responses by NK cells
- (2014) Nina Le Bert et al. IMMUNOLOGY AND CELL BIOLOGY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- In vivo albumin labeling and lymphatic imaging
- (2014) Yu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
- (2014) B. Weide et al. Cancer Immunology Research
- A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
- (2013) Joseph P Connor et al. BMC CANCER
- Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival
- (2013) Richard K. Yang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia
- (2013) K. L. Gutbrodt et al. Science Translational Medicine
- Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
- (2012) Mark R. Albertini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin-Positive Metastatic Human Melanoma Xenografts
- (2012) M. Moschetta et al. CANCER RESEARCH
- Immunocytokines: a novel class of potent armed antibodies
- (2012) Nadine Pasche et al. DRUG DISCOVERY TODAY
- Fc-fusion proteins: new developments and future perspectives
- (2012) Daniel M. Czajkowsky et al. EMBO Molecular Medicine
- A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
- (2012) Silke Gillessen et al. EUROPEAN JOURNAL OF CANCER
- Crystal Structure of the Cowpox Virus-Encoded NKG2D Ligand OMCP
- (2012) E. Lazear et al. JOURNAL OF VIROLOGY
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Tumor-Targeted Delivery of IL-2 by NKG2D Leads to Accumulation of Antigen-Specific CD8+ T Cells in the Tumor Loci and Enhanced Anti-Tumor Effects
- (2012) Tae Heung Kang et al. PLoS One
- Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
- (2012) Frederick Lansigan Cancer Management and Research
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
- (2011) T. K. Eigentler et al. CLINICAL CANCER RESEARCH
- A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
- (2011) S. D. Gillies et al. CLINICAL CANCER RESEARCH
- Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine
- (2011) Xianming Huang et al. VACCINE
- Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
- (2010) M Pedretti et al. BRITISH JOURNAL OF CANCER
- The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
- (2010) Manfred Johannsen et al. EUROPEAN JOURNAL OF CANCER
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- The Immunocytokine F8-IL2 Improves the Therapeutic Performance of Sunitinib in a Mouse Model of Renal Cell Carcinoma
- (2010) Katharina Frey et al. JOURNAL OF UROLOGY
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer
- (2009) Nicolas Acquavella et al. JOURNAL OF IMMUNOTHERAPY
- Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
- (2009) Antoni Ribas et al. Journal of Translational Medicine
- Intratumoral immunocytokine treatment results in enhanced antitumor effects
- (2008) Erik E. Johnson et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer
- (2008) K. Wagner et al. CLINICAL CANCER RESEARCH
- Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
- (2008) J. Marlind et al. CLINICAL CANCER RESEARCH
- The Biology of Interleukin-2
- (2007) Thomas R. Malek Annual Review of Immunology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started